Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Technology evaluation: denosumab, Amgen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

OriginalsprogEngelsk
TidsskriftCurrent Opinion in Molecular Therapeutics
Vol/bind7
Udgave nummer6
Sider (fra-til)604-10
Antal sider7
ISSN1464-8431
StatusUdgivet - dec. 2005
Eksternt udgivetJa

ID: 44264435